Shawn M OConnell
Overview
Explore the profile of Shawn M OConnell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bennett M, Wu Y, Boloor A, Matuszkiewicz J, OConnell S, Shi L, et al.
Bioorg Med Chem Lett
. 2018 Apr;
28(10):1811-1816.
PMID: 29657099
The bromodomain and extra-terminal (BET) family of epigenetic proteins has attracted considerable attention in drug discovery given its involvement in regulating gene transcription. Screening a focused small molecule library based...
2.
Nie Z, Shi L, Lai C, OConnell S, Xu J, Stansfield R, et al.
Bioorg Med Chem Lett
. 2018 Apr;
28(9):1490-1494.
PMID: 29627262
Histone lysine demethylases (KDMs) play a key role in epigenetic regulation and KDM5A and KDM5B have been identified as potential anti-cancer drug targets. Using structural information from known KDM4 and...
3.
Chen Y, Bonaldi T, Cuomo A, Del Rosario J, Hosfield D, Kanouni T, et al.
ACS Med Chem Lett
. 2017 Aug;
8(8):869-874.
PMID: 28835804
Histone lysine demethylases (KDMs) play a vital role in the regulation of chromatin-related processes. Herein, we describe our discovery of a series of potent KDM4 inhibitors that are both cell...
4.
Micel L, Tentler J, Tan A, Selby H, Brunkow K, Robertson K, et al.
Mol Cancer Ther
. 2014 Nov;
14(2):317-25.
PMID: 25376610
The goal of this study was to investigate the activity of the selective MEK1/2 inhibitor TAK-733 in both melanoma cell lines and patient-derived melanoma xenograft models. In vitro cell proliferation...
5.
Adams M, Wallace M, Kanouni T, Scorah N, OConnell S, Miyake H, et al.
Bioorg Med Chem Lett
. 2012 Mar;
22(7):2411-4.
PMID: 22406151
The structure-based design, synthesis, and biological evaluation of two novel series of potent and selective MEK kinase inhibitors are described herein. The elaboration of a lead pyrrole derivative to a...
6.
Dong Q, Dougan D, Gong X, Halkowycz P, Jin B, Kanouni T, et al.
Bioorg Med Chem Lett
. 2011 Feb;
21(5):1315-9.
PMID: 21310613
A novel 5-phenylamino-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione series of MEK inhibitors has been developed using structure-based drug design. Lead optimization of this series led to the discovery of TAK-733. This was advanced to Phase...
7.
Wallace M, Adams M, Kanouni T, Mol C, Dougan D, Feher V, et al.
Bioorg Med Chem Lett
. 2010 Jul;
20(14):4156-8.
PMID: 20621728
A novel series of pyrrole inhibitors of MEK kinase has been developed using structure-based drug design. Optimization of the series led to the identification of potent inhibitors with good pharmaceutical...